Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: A Phase II study

Francesco Deodato, Maria Antonietta Gambacorta, Mario Balducci, Gian Carlo Mattiucci, Vincenzo Valentini, Alessio Giuseppe Morganti, Francesco Cellini, Samantha Mignogna, Luciana Caravatta, Vincenzo Picardi, Savino Cilla, Rosa Autorino, Gilbert Da Padula, Gabriella Macchia, Milly Buwenge, Liberato Di Lullo

Risultato della ricerca: Contributo in rivistaArticolo in rivista

2 Citazioni (Scopus)

Abstract

Aims: Low-dose radiation therapy (LDRT) can increase biological efficacy of chemotherapy. This Phase II trial evaluates LDRT plus FOLFIRI-bevacizumab (FOLFIRI-B) in metastatic colorectal cancer. Materials & methods: Primary objective: raising the clinical complete response rate from 5 to 25%. Secondary objectives: toxicity, progression-free survival. Patients underwent 12 FOLFIRI-B cycles plus two daily LDRT fractions (20 cGy/6 h interval) on each cycle. Statistical analysis was planned on 18 patients. Results: Results on 18 patients are reported. Specifically considering irradiated sites: 15/18 patients had a partial (11/18) or complete (4/18) response. Among 11 partial responders, three became a pathological CR after surgery. Grade 3-4 toxicity was recorded in two patients (11.1%). At median follow-up of 30 months (range: 8-50), 7/18 patients progressed in irradiated sites. Conclusion: Seven out of 18 patients (38.9%) had clinical or pathological CR in lesions treated with LDRT. Further studies on this newer treatment modality seem justified.
Lingua originaleEnglish
pagine (da-a)779-787
Numero di pagine9
RivistaFuture Oncology
Volume12
DOI
Stato di pubblicazionePubblicato - 2016

Keywords

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Bevacizumab
  • Camptothecin
  • Cancer Research
  • Chemoradiotherapy
  • Colorectal Neoplasms
  • Female
  • Fluorouracil
  • Humans
  • Leucovorin
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Oncology
  • Phase II
  • Radiotherapy Dosage
  • Treatment Outcome
  • bevacizumab
  • chemo-sensitization
  • low-dose radiotherapy
  • metastatic colorectal cancer
  • multidisciplinary integrated treatments

Fingerprint Entra nei temi di ricerca di 'Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: A Phase II study'. Insieme formano una fingerprint unica.

Cita questo